Compositions and methods for rapid and reversible biomolecular labeling
US-2024426816-A1 · Dec 26, 2024 · US
US2021009946A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2021009946-A1 |
| Application number | US-201816755370-A |
| Country | US |
| Kind code | A1 |
| Filing date | Oct 15, 2018 |
| Priority date | Oct 13, 2017 |
| Publication date | Jan 14, 2021 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a method of screening highly efficiently stem cells using the protein marker GRP78, and more particularly, to a method of removing old stem cells with decreased expression of GRP78 and isolating only highly efficient stem cells. The use of the protein marker GRP78 according to the present invention makes it possible to isolate only highly efficient stem cells by removing old stem cells. Thus, the protein marker GRP78 may be used as an effective marker for controlling the quality of stem cell therapy products and evaluating the stability and effectiveness thereof, and is useful in the production of stem cell therapy products having excellent therapeutic efficacy.
Opening claim text (preview).
1 . A method of isolating highly efficient stem cells using an antibody or aptamer specific for GRP78. 2 . The method of claim 1 , comprising steps of: (a) binding a GRP78-specific primary antibody to stem cells; (b) binding a secondary antibody-immobilized magnetic bead to the primary antibody; and (c) isolating GRP78-expressing stem cells using MACS (magnetic-activated cell sorting). 3 . The method of claim 1 , wherein the highly efficient stem cells express GRP78 in the membrane. 4 . The method of claim 2 , wherein step (c) further comprises a step of removing stem cells expressing a low level of GRP78 in the membrane. 5 . The method of claim 4 , wherein the stem cells expressing a low level of GRP78 in the membrane are old stem cells. 6 . A composition for screening highly efficient stem cells, the composition comprising an agent capable of measuring the expression level of mRNA of GRP78 gene or a protein encoded by the gene. 7 . The composition of claim 6 , wherein the agent capable of measuring the expression level of the mRNA is a primer capable of amplifying the GRP78 gene or a probe that binds specifically to the GRP78 gene. 8 . The composition of claim 6 , wherein the agent capable of measuring the expression level of the protein is an antibody or aptamer specific for the protein encoded by the GRP78 gene. 9 . The composition of claim 6 , wherein the highly efficient stem cells are non-senescent young stem cells. 10 . A kit for screening highly efficient stem cells, the kit comprising the composition of claim 6 . 11 . The kit of claim 10 , wherein the kit is an RT-PCR kit, a DNA chip kit or a protein chip kit. 12 . A method for screening highly efficient stem cells, the method comprising steps of: (a) extracting a DNA or protein from stem cells; (b) measuring the expression level of mRNA of GRP78 gene or a protein encoded by the gene; (c) comparing the measured expression level of mRNA of the gene or the protein encoded by the gene with a control; and (d) selecting the stem cells as highly efficient stem cells if the expression level increases compared to the control. 13 . The method of claim 12 , wherein the expression level of mRNA of the gene is measured by any one selected from the group consisting of polymerase chain reaction (PCR), reverse transcription-polymerase chain reaction (RT-PCR), real-time PCR, RNase protection assay (RPA), microarray, and Northern blotting. 14 . The method of claim 12 , wherein the expression level of the protein is measured by any one selected from the group consisting of Western blotting, radioimmunoassay (RIA), radioimmunodiffusion, enzyme-linked immunosorbent assay (ELISA), immunoprecipitation, flow cytometry, immunofluorescence assay, Ouchterlony assay, complement fixation assay, and protein chip assay. 15 . The method of claim 12 , wherein the control is old stem cells. 16 . The method of claim 12 , wherein the highly efficient stem cells are non-senescent young stem cells.
Animal cells · CPC title
Stem cells · CPC title
Expression markers · CPC title
Purging biological preparations of unwanted cells · CPC title
against receptors, cell surface antigens or cell surface determinants · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.